Common Contracts

33,333,350 Shares of Common Stock BIONANO GENOMICS, INC. UNDERWRITING AGREEMENT

Underwriting Agreement • January 21st, 2021 • Bionano Genomics, Inc • Laboratory analytical instruments • New York

• Contract Type
  Underwriting Agreement
• Filed
  January 21st, 2021
• Company
  Bionano Genomics, Inc
• Industry
  Laboratory analytical instruments
• Jurisdiction
  New York

Bionano Genomics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Oppenheimer & Co. Inc., as representative (the “Representative”) of the several underwriters named in Schedule I hereto (each, an “Underwriter” and collectively, the “Underwriters”), an aggregate of 33,333,350 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 5,000,002 shares (the “Company Option Shares”) of Common Stock from the Company for the purpose of covering over‑allotments in connection with the sale of the Firm Shares. The Firm Shares and the Company Option Shares are collectively called the “Shares.”

29,016,393 Shares of Common Stock BIONANO GENOMICS, INC. UNDERWRITING AGREEMENT

Underwriting Agreement • January 11th, 2021 • Bionano Genomics, Inc • Laboratory analytical instruments • New York

• Contract Type
  Underwriting Agreement
• Filed
  January 11th, 2021
• Company
  Bionano Genomics, Inc
• Industry
  Laboratory analytical instruments
• Jurisdiction
  New York

Bionano Genomics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Oppenheimer & Co. Inc., as representative (the “Representative”) of the several underwriters named in Schedule I hereto (each, an “Underwriter” and collectively, the “Underwriters”), an aggregate of 29,016,393 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 4,352,458 shares (the “Company Option Shares”) of Common Stock from the Company for the purpose of covering over‑allotments in connection with the sale of the Firm Shares. The Firm Shares and the Company Option Shares are collectively called the “Shares.”